Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 6Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Ovarian Neoplasms 1Non Small Lung Cancer 1Neoplasms by Site 1Lung Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Efficacy 1Carcinoma 1Bronchial Neoplasms 1Advanced Solid Tumors 1Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation 1Adenocarcinoma of Lung 1

Interventions

durvalumab 3Carboplatin 2sotorasib 1sintilimab 1necitumumab 1ceralasertib 1camrelizumab 1apatinib 1alectinib 1Radiotherapy 1Radiosurgery 1Gemcitabine 1Etoposide 1Erlotinib Hydrochloride 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Respiratory Tract Diseases × sotorasib × Clear all
NCT05054725 2026-01-06

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Revolution Medicines, Inc.

Phase 2 Completed
47 enrolled 17 charts
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Respiratory Tract Diseases, Respiratory Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡